$\mathcal{JFW}$

CASE D0273 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Stephen C. D'Amico		8-17-04
Type or print name	Signature	Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

HUANG ET AL.

APPLICATION NO: 10/648,593

FILED: AUGUST 26, 2003

FOR: IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING ACTIVITY OF COMPOUNDS THAT INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE KINASES AND/OR PROTEIN TYROSINE KINASE PATHWAYS IN BREAST CELLS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289

Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: 8-17-04

FORM PTO-1449   U.S. DEPARTMENT OF COMMERCE   ATTY. DOCKET NO.
(REV. 7-85)   PATENT AND TRADEMARK OFFICE   D0273 NP
INFORMATION DISCLOSURE CITATION
                                                           APPLICATION NO.
                                                           10/648,593
(Use several sheets if necessary)   APPLICANT
                                                           HUANG ET AL.
                                                           FILING DATE   Group
                                                           AUGUST 26, 2003

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	US5569588	10/29/96	Ashby, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
	AM						☐	☐
	AN						☐	☐
	AO						☐	☐
	AP						☐	☐
	AQ						☐	☐

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Cockett, et al., "Applied genomics:integration of the technology within pharmaceutical research and development", Current Opinion in Biotech, Vol. 11, pp. 602-609 (2000)
	AS	Sonneveld, P., "Multidrug resistance in haematological malignancies", J. Internal Med., Vol. 247, pp. 521-534 (2000)
	AT	Alizadeh, et al., "Distinct types of diffuse large B-cell lymphoma identifie by gene expression profiling", Nature, Vol. 403, pp. 503-511 (2000)

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
D0273 NP
APPLICATION NO.
10/648,593

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT
HUANG ET AL.
FILING DATE   Group
AUGUST 26, 2003

OIPE
AUG 1 9 2004
JC24
PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	2AA	Bittner, et al., "Molecular classification of cutaneous malignant melanoma by gene expression profiling", Nature, Vol. 406, pp. 536-540 (2000)
	2AB	van't Veer, et al., "Gene expression profiling predicts clinical outcome of breast cancer", Nature, Vol. 15, pp. 530-536 (2002)
	2AC	Khan, et al., "Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks", Nature Medicine, Vol. 7, pp. 673-679 (2001)
	2AD	Shipp, et al., "Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning", Nature Medicine, Vol. 8, pp. 68-74 (2002)
	2AE	Golub, et al., "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", Science, Vol. 286, pp. 531-537 (1999)
	2AF	Alon, et al., "Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays", PNAS, Vol. 96, pp. 6745-6750 (1999)
	2AG	West, et al., "Predicting the clinical status of human breast cancer by using gene expression profiles", PNAS, Vol. 98(20), pp. 11462-11467 (2001)
	2AH	Sorlie, et al., "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications", PNAS, Vol. 98(19), pp. 10869-10874 (2001)
	2AI	Blanchard, et al., "Sequence to array: Probing the genome's secrets", Nature Biotechnology, Vol. 14, pp. 1649 (1996)
	2AJ	Khan, et al., "Gene Expression Profiling of Alveolar Rhabdomyosarcoma with cDNA Microarrays", Cancer Res., Vol. 58, pp. 5009-5013 (1998)
	2AK	Lockhart, et al., "Expression monitoring by hybridization to high-density oligonucleotide arrays", Nature Biotechnology, Vol. 14, pp. 1675-1680 (1996)
	2AL	Freeman, et al., "Fundamentals of DNA Hybridization Arrays for Gene Expression Analysis", BioTechniques, Vol. 29, pp. 1042-1055 (2000)
	2AM	Schena, et al., "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray", Science, Vol. 270, pp. 467-470 (1995)
	2AN	

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.